News

Itepekimab Met Primary Endpoint In One Of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...
'I lost 6stone with weight loss jabs but there's one side-effect no one tells you about'
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Regeneron Pharmaceuticals, Inc.: Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...